Andrew N. Ming-Lum, PhD Associate


Speaks:  English

Year of Call: 2016 - British Columbia


Primary office:  Vancouver




Andrew N. Ming-Lum, PhD

Andrew Ming-Lum is an associate in Gowling WLG's Vancouver office, practising in the Intellectual Property and Life Science groups.

Andrew assists clients in patent drafting and prosecution, with a focus on inventions in the biotechnology, immunology, molecular biology and biochemistry fields. Andrew also advises clients on other patent-related issues, such as validity, infringement and freedom-to-operate.

Additionally, Andrew supports clients in various business matters including the incorporation and organization of a company, and drafting of confidentiality, licensing and technology transfer agreements.

Andrew brings a wealth of life science research and experience to his practice. Prior to becoming a lawyer, Andrew earned his doctorate in Experimental Medicine from the University of British Columbia, where his research led to the characterization and development of novel anti-inflammatory therapeutics. He also worked for several years in the pre-clinical pharmacology department of a Vancouver-based pharmaceutical company.


 

Career & Recognition

Filter timeline:
  • 2016

    • Qualifications (Year of Call/Admission, etc.)
      2016
      Year of Call, British Columbia
  • 2015

    • Education
      2015
      University of British Columbia, JD
  • 2012

    • Education
      2012
      University of British Columbia, PhD in Experimental Medicine
  • 2002

    • Education
      2002
      Queen's University, B.Sc. (Hons.) Life Sciences

Richard Johnson & Andrew Ming-Lum (co-authors) “Chapter 11: Government Policies to Encourage Innovation” in Martin P.J. Kratz, Q.C. & Kevin L. Laroche, eds, The Business of Innovation – Intellectual Property Transactions and Strategies in the New Economy (Toronto, Carswell 2016).

Andrew has experience in drafting and prosecuting patents in various technological disciplines, including small molecule pharmaceuticals, biological therapeutics, medical diagnostics and mechanical devices. He has also been involved in the incorporation and organization of tech startups and corporate transactions where intellectual property comprises the principal asset.